Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

From the call, the analyst notes that feedback on Teva's/Sanofi's SNY anti-TL1A antagonist duvakitug, along with the broader anti-TL1A class, suggests these agents could play a significant role in ...

Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027.

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on ...